FY2025 Earnings Estimate for Acasti Pharma Inc. Issued By HC Wainwright (NASDAQ:ACST)

Acasti Pharma Inc. (NASDAQ:ACST) – Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Acasti Pharma in a research report issued to clients and investors on Monday, July 1st. HC Wainwright analyst O. Livnat now anticipates that the biopharmaceutical company will post earnings per share of ($1.14) for the year, up from their previous estimate of ($1.29). The consensus estimate for Acasti Pharma’s current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Acasti Pharma’s FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.83) EPS.

Acasti Pharma Trading Up 1.8 %

NASDAQ:ACST opened at $2.90 on Wednesday. Acasti Pharma has a 12-month low of $1.72 and a 12-month high of $3.84. The stock has a 50-day moving average price of $2.93 and a 200 day moving average price of $2.95. The stock has a market capitalization of $27.26 million, a P/E ratio of -2.01 and a beta of 1.55.

Acasti Pharma (NASDAQ:ACST) last released its earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.30.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.